Dyspnea and antiplatelet drugs: Little cause for concern with clopidogrel

Rickard E. Malmström; Paul Hjemdahl

doi:10.1160/TH08-08-0545

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(04): 517-518
DOI: 10.1160/TH08-08-0545

Editorial Focus

Schattauer GmbH

Dyspnea and antiplatelet drugs: Little cause for concern with clopidogrel

Authors

Rickard E. Malmström

¹Department of Medicine Solna, Clinical Pharmacology Unit, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden
Paul Hjemdahl

¹Department of Medicine Solna, Clinical Pharmacology Unit, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden

Abstract

Full Text

References

References
1 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
2 Storey RF, Husted S, Harrington RA. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-1856.
3 Husted S, Emanuelsson H, Heptinstall S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y₁₂ antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
4 Cannon CP, Husted S, Harrington RA. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
5 Serebruany VL, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract 2007; 61: 529-533.
6 Husted S, van Giezen JJJ. Dyspnoea and antiplatelet agents: revisited. Int J Clin Pract 2007; 61: 1590-1591.
7 Serebruany V, Pokov I, Kuliczkowski W. et al. Incidence and causes of new-onset dyspnea in 3,179 patients treated with clopidogrel and aspirin combination after coronary stenting. Thromb Haemost 2008; 100: 314-318.